Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
Eli Lilly's experimental once-weekly injection retatrutide yielded up to 25 percent weight loss in a Phase 3 clinical trial. The triple hormone receptor agonist also demonstrated better blood sugar control alongside reported side effects such as nausea and diarrhea in trials evaluating its ability to treat obesity and type 2 diabetes. While tirzepatide and semaglutide hold current regulatory approvals, retatrutide remains unapproved by regulators as drug developers continue evaluating advanced obesity treatments.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Eli Lilly's experimental once-weekly injection retatrutide targets three hormone receptors at once.
- β Retatrutide achieved up to 25 percent body weight reduction in a clinical trial.
- β Eli Lilly plans to file for regulatory approval of retatrutide in the first quarter of 2027.
What changed
A Phase 3 trial evaluated retatrutide and demonstrated up to 25 percent weight loss alongside side effects like nausea and diarrhea.
Live updates
-
Eli Lilly Retatrutide Shows Up to 25% Weight Loss in Phase 3
Eli Lilly's experimental once-weekly injection retatrutide yielded up to 25 percent weight loss in a Phase 3 clinical trial. The triple hormone receptor agonist also demonstrated better blood sugar control alongside reported side effects such as nausea and diarrhea in trials evaluating its ability to treat obesity and type 2 diabetes. While tirzepatide and semaglutide hold current regulatory approvals, retatrutide remains unapproved by regulators as drug developers continue evaluating advanced obesity treatments.
Why it matters
Retatrutide differs from existing medications by targeting three hormone receptors simultaneously instead of one or two. Eli Lilly plans to file for regulatory approval for the experimental drug in the first quarter of 2027. Meanwhile, competitive positioning among existing treatments continues to evolve, highlighted by trials comparing medications like Zepbound and Wegovy.
What is confirmed
- Eli Lilly's experimental once-weekly injection retatrutide targets three hormone receptors at once.
- Retatrutide achieved up to 25 percent body weight reduction in a clinical trial.
- Eli Lilly plans to file for regulatory approval of retatrutide in the first quarter of 2027.
Still unconfirmed
- Reports have emerged linking illicit, unapproved versions of retatrutide to severe side effects in unlicensed users.
What to watch next
- Eli Lilly's planned regulatory filing for retatrutide in the first quarter of 2027.
- Additional data releases from ongoing retatrutide clinical trials.
confidence 100%Sources used for this update (10)
- pharmaphorum.com β Zepbound tops Wegovy in first head-to-head weight-loss trial
- www.healthcount.app β Eloralintide Plus Tirzepatide (EloraTZP), Explained | Healthcount
- scitechdaily.com β Beyond Ozempic? New Weight Loss Drug Shows Stunning Results ...
- puripharmacy.co.uk β Is Retatrutide Better Than Ozempic? - puripharmacy.co.uk
- www.aestheticsadvisor.com β Retatrutide vs Tirzepatide vs Semaglutide (Ozempic): GLP-1 ...
- medicalxpress.com β Triple-action drug retatrutide delivers major weight loss for ...
- www.diabetes.co.uk β Retatrutide delivers 18.8% average weight loss in Phase III ...
- therxindex.com β Retatrutide Clinical Trials: 32 Studies, 2 Open | The RX ...
- peptidechecked.com β Semaglutide vs Tirzepatide: Trial Results Compared
- frnt.com β Experimental Weight-Loss Drug Retatrutide Linked to Diverse ...
-
Eli Lilly Retatrutide Phase 3 Data Shows Weight Loss Up to 28.3%
Eli Lilly's experimental weekly injection retatrutide yielded significant weight reductions in late-stage clinical trials, including an average of 28.3 percent at 80 weeks in the TRIUMPH-1 trial at the highest dose. Full Lancet results for adults with type 2 diabetes and a body mass index of 35 or higher showed a 23.4 percent weight loss, while adults with obesity and type 2 diabetes lost an average of 18.8 percent at week 80 with the 12 milligram dose compared to 5.1 percent on placebo. The triple agonist drug remains unapproved by regulators.
Why it matters
Retatrutide represents part of a second wave of obesity medicines known as GLP-1 2.0, which build on earlier drugs like semaglutide and tirzepatide by introducing greater potency, new mechanisms such as amylin and glucagon, easier formats, and improved body composition. Eli Lilly plans to file for FDA approval of retatrutide in the first quarter of 2027. Meanwhile, competitive dynamics in the market continue to evolve as head-to-head data backs Zepbound over Wegovy.
What is confirmed
- Eli Lilly's retatrutide averaged 28.3 percent weight loss at 80 weeks in the TRIUMPH-1 trial at the highest dose.
- Full Lancet results show 23.4 percent weight loss in adults with type 2 diabetes and a BMI of 35 or higher.
- Adults with obesity and type 2 diabetes lost an average of 18.8 percent of body weight at week 80 with retatrutide 12 mg, versus 5.1 percent with placebo.
- Retatrutide remains unapproved by regulatory authorities.
Still unconfirmed
- Eli Lilly plans to file retatrutide for FDA approval in the first quarter of 2027.
What to watch next
- Eli Lilly's planned FDA filing for retatrutide in the first quarter of 2027
- Upcoming regulatory decisions for other next-generation obesity drugs like CagriSema in late 2026
confidence 90%Sources used for this update (7)
- www.medicaldaily.com β Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in ...
- theclinicaltimes.com β Retatrutide led to weight loss in phase III trial of adults ...
- www.onedaymd.com β GLP-1 2.0: The Next Generation of Obesity Drugs - onedaymd.com
- www.news-age.com β Beyond Ozempic: Eli Lillyβs Experimental Drug Delivers Up to ...
- pharmaphorum.com β More data backs Zepbound over Wegovy for weight loss
- vialaudit.com β Retatrutide Phase 3 results: TRIUMPH-2 in The Lancet
- glp1watchdog.com β Mounjaro vs Ozempic 2026: Full Comparison & Verdict
-
Retatrutide Phase 3 Trial Shows 25% Weight Loss
An experimental weekly injection called retatrutide achieved an average weight reduction of 25 percent among participants taking the highest dose during an 80-week Phase 3 clinical trial. Developed by Eli Lilly, the drug also demonstrated positive effects on related medical issues, including reduced knee pain and improvements in sleep apnea symptoms. Beyond retatrutide, Eli Lilly advanced other pipeline combinations such as EloraTZP, an experimental combination of eloralintide and tirzepatide that delivered greater weight loss and A1C reductions compared to tirzepatide 15 milligrams in adults with obesity and type 2 diabetes.
Why it matters
The pharmaceutical industry is aggressively pursuing new treatments leveraging amylin and multi-receptor mechanisms following the massive commercial adoption of standard GLP-1 medications like Ozempic and Zepbound. These next-generation combinations seek to push efficacy boundaries further by targeting multiple metabolic pathways simultaneously. The trial results mark a significant benchmark in anti-obesity drug development as developers try to address both severe weight reduction and secondary complications such as joint strain and breathing disorders.
What is confirmed
- Participants taking the highest dose of retatrutide lost an average of 25% of their starting weight over an 80-week period in a Phase 3 trial.
- The retatrutide trial reported improvements in knee pain and reductions in sleep apnea symptoms.
- Lilly's EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1C reduction versus tirzepatide 15 mg in adults with obesity and type 2 diabetes.
What to watch next
- Further regulatory filings and trial data releases for retatrutide and EloraTZP from Eli Lilly.
- Broader industry updates on amylin-based obesity drug pipelines from competitors like Novo Nordisk.
confidence 100%Sources used for this update (14)
- The Guardian β βGodzillaβ of weight-loss drugs could provide other important health benefits
- Scientific American β Blockbuster retatrutide trial signals a βnew high-water markβ for weight-loss drugs
- Eli Lilly β Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- Reuters β Experimental Lilly combination drug tops Zepbound in weight-loss trial
- USA Today β Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
- Fierce Biotech β Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
- WSJ β Lillyβs Next-Gen Obesity Drug Helps People Lose Even More Weight in Study
- CNBC β Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- ScienceAlert β Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
- www.sciencealert.com β Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
- www.glp3.wiki β Retatrutide Results and Review: The Weight Loss Data by Dose
- www.dazzr.com β Ozempic Rival Delivers 25% Weight Loss at Highest Dose in ...
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community